Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SelangBio
- Ownership
- Private
- Development stage
- Other
01
Overview
SelangBio appears to be a life sciences company focused on CAR-T cell therapies in China. Publicly accessible information on the company is very limited, but third-party industry reporting identifies SelangBio as a sponsor of multiple CAR-T clinical trials in China as of 2021. Based on the available evidence, the company seems to operate in oncology and cell therapy rather than as a service provider such as a CRO or CDMO. Because primary company materials were not readily identifiable, important details such as its formal legal name, headquarters, management team, and named pipeline assets could not be confirmed from authoritative sources.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on SelangBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SelangBio.